SRF Publications

If you are looking for an accessible description of SENS research, our Chief Science Officer, Dr Aubrey de Grey, together with co-author Michael Rae, has written a book entitled Ending Aging. The book speaks to a broad audience, but it does so without ‘dumbing down’ the science at all. It is the ideal resource for either the biologist or the non-biologist, whether encountering SENS for the first time or wishing to absorb more of its details. Copies are available from your local bookstore or from Amazon.com. The details are: de Grey ADNJ, Rae M. Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime. New York, NY: St. Martin’s Press, 2007, 416pp, hardcover, ISBN 0-312-36706-6; or there is a paperback edition with an additional chapter covering more recent developments, ISBN 0-312-36707-4. Thanks to narrator Stephanie Murphy, there’s now even an audiobook version!

Ending Aging is also available in Spanish, Japanese, German, and Portuguese (via Amazon Brazil / via Amazon US).

The following list of publications presents work which was funded in whole or in part by SENS Research Foundation.

  • Kim NY, Goddard TN, Sohn S, Spiegel DA, Crawford J. Biocatalytic Reversal of Advanced Glycation End Product Modification. Chembiochem. 2019 Apr 23. PubMed: 31013547.
  • Chow WY, Li R, Goldberga I, Reid DG, Rajan R, Clark J, Oschkinat H, Duer MJ, Hayward R, Shanahan CM. Essential but sparse collagen hydroxylysyl post-translational modifications detected by DNP NMR. Chem Commun (Camb). 2018 Nov 6;54(89):12570-12573. PubMed: 30299444
  • Perrott KM, Wiley CD, Desprez PY, Campisi J. Apigenin suppresses the senescence-associated secretory phenotype and paracrine effects on breast cancer cells. Geroscience. 2017 Apr;39(2):161-173. PubMed: 28378188
  • Rebo J, Mehdipour M, Gathwala R, Causey K, Liu Y, Conboy MJ, Conboy IM. A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old blood. Nat Commun. 2016 Nov 22;7:13363. PubMed: 27874859.
  • Boominathan A, Vanhoozer S, Basisty N, Powers K, Crampton AL, Wang X, Friedricks N, Schilling B, Brand MD, O’Connor MS. Stable nuclear expression of ATP8 and ATP6 genes rescues a mtDNA Complex V null mutant. Nucleic Acids Res. 2016 Sep 4. PubMed: 27596602
  • Gravina S, Dong X, Yu B, Vijg J. Single-cell genome-wide bisulfite sequencing uncovers extensive heterogeneity in the mouse liver methylome. Genome Biol. 2016 Jul 5;17(1):150. PubMed: 27380908
  • Pettitt DA, Smith J, Meadows N, Arshad Z, Schuh A, DiGustio D, Bountra C, Holländer G, Barker R, Brindley DA. Regulatory barriers to the advancement of precision medicine. Expert Review of Precision Medicine and Drug Development 1: 319-329. Read on external site.
  • Pettitt DA, Smith J, Fuzerstenau-Sharp M, Holländer G, Predki P, Slade A, Jones P, Weed L, Bure K, Brindley DA. Emerging Platform Bioprocesses for Viral Vectors and Gene Therapies. BioProcess International 14(4)s. Read on external site.
  • Bure K, Ball A, Biagioni K, Mehta S, Choudhary R, Arshad Z, Pettitt DA, Holländer G, Al-Mossawi H, Faulstich F, Reeve B, Smith JA, Brindley DA. Automation of CAR-T Cell Adoptive Immunotherapy Bioprocessing. BioProcess International 14(4)s. Read on external site.
  • Pettitt DA, Raza S, Naughton B, Roscoe A, Ramakrishnan A, Ali A, Davies B, Dopson S, Hollander G, Smith J, Brindley DA. The Limitations of QALY: A Literature Review. J Stem Cell Res Ther 6:334. Read on external site.
  • Arshad Z, Smith J, Roberts M, Lee WH, Davies B, Bure K, Hollander GA, Dopson S, Bountra C, Brindley D. Open Access Could Transform Drug Discovery: A Case Study of JQ1. Expert Opin Drug Discov. 2016 Mar;11(3):321-32. PubMed: 26791045.
  • Wiley CD, Velarde MC, Lecot P, Liu S, Sarnoski EA, Freund A, Shirakawa K, Lim HW, Davis SS, Ramanathan A, Gerencser AA, Verdin E, Campisi J. Mitochondrial Dysfunction Induces Senescence with a Distinct Secretory Phenotype. Cell Metab. 23(2):303-14. PubMed: 26686024
  • Gaspar J, Mathieu J, Alvarez PJJ. A Rapid Platform to Generate Lipofuscin and Screen Therapeutic Drugs for Efficacy in Lipofuscin Removal. Materials, Methods & Technologies, Volume 10, 2016. Read on external site.
  • Naughton BD, Smith JA, Brindley DA. Establishing good authentication practice (GAP) in secondary care to protect against falsified medicines and improve patient safety. Eur J Hosp Pharm doi:10.1136/ejhpharm-2015-000750. Read on external site.
  • Smith JA, French A, Hurley H, Davies B, Dopson S, Fairchild P, Roberts M, Riley P, Reeve B, Williams D, Daheron L, Bure K, Carr A, Karp JM, Wall I, Brindley D. Challenges and Opportunities in the Development of Induced Pluripotent Stem Cell Therapeutics. In: Frontiers in Stem Cell and Regenerative Medicine Research, Volume II. Bentham Science (in press). Read on external site.
  • Smith JA, Dopson S, Davies B, Wartolowska K, Karp JM, Carr AJ, Brindley DA. Borderline Regulation of Stem Cell Technologies: Therapies, Devices and Combination Products. In: Global Device Strategy. Regulatory Affairs Professionals Society (in press).
  • Rekhi R, Smith JA, Arshad Z, Roberts M, Bountra C, Bingham I, Bure K, Brindley DA. Decision-Support Tools for Monoclonal Antibody and Cell Therapy Bioprocessing: Current Landscape and Development Opportunities. BioProcess Executive 13(11). Read on external site.
  • Luo D, Smith JA, Meadows NA, Manescu K, Bure K, Davies B, Horne R, DiGiusto DL, Brindley DA. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics. Front. Genet. 6:357. Read on external site.
  • Lannon KA, Smith JA, Bure K, Brindley DA. Quantitative Risk Assessment of Bioaccumulation Attributable to Extractables and Leachables in Cellular Immunotherapy Biomanufacturing. BioProcess International. (Nov 2015) Read on external site.
  • Carmen J, Brindley DA, Davie NL, Smith D. Cell Therapy Manufacturing: Identifying and Meeting Demand. In: Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies. Wiley-Blackwell (2015). Read on external site.
  • Draghici C, Wang T, Spiegel DA. Concise total synthesis of glucosepane. Science 2015;350(6258):294-298. doi:10.1126/science.aac9655. PubMed: 26472902.
  • Phay M, Welzel AT, Williams AD, McWilliams-Koeppen HP, Blinder V, O’Malley TT, Solomon A, Walsh DM, O’Nuallain B. IgG Conformer’s Binding to Amyloidogenic Aggregates. PLoS One. 2015 Sep 14;10(9):e0137344. doi: 10.1371/journal.pone.0137344. PubMed: 26367058
  • Brindley DA, Arshad Z, Luo D, Dopson S, Hollander G, Frost S, Bountra C, Smith JA. 21(st) Century Cures Act: An Act of Cure or Diagnosis? Rejuvenation Res. 2015 Aug;18(4):295-8. PubMed: 26291241.
  • Hughes BB, Kuhn R, Margolese-Malina ES, Rothman DS, Solórzano JR. Opportunities and challenges of a world with negligible senescence. Technol. Forecast. Soc. Change 99:77-91 (2015). Read on external site.
  • Gravina S, Ganapathi S, Vijg J. Single-cell, locus-specific bisulfite sequencing (SLBS) for direct detection of epimutations in DNA methylation patterns. Nucleic Acids Res. 2015 Apr 19. pii: gkv366. PubMed: 25897117.
  • Brindley DA, Rekhi R, Fuerstenau-Sharp M, Kantoff PW, Hollander GA, Smith JA, Tindal S, Timmins N, Bure K. The Potential Application of Real Time Release Testing for the Biomanufacture of Autologous Cell Based Immunotherapies. BioProcess International. 13(4):1-8. Read on external site.
  • Smith JA, Ng KS, Mead BE, Dopson S, Reeve B, Edwards J, Wood MJA, Carr AJ, Bure K, Karp JM, Brindley DA. Extracellular Vesicles: Commercial Potential As Byproducts of Cell Manufacturing for Research and Therapeutic Use. BioProcess International. 13(4). Read on external site.
  • Silva H, Halvorsen D, Henson JD. Control ALT, Delete Cancer The Scientist (magazine). Read on external site. 
  • French A, Bravery C, Smith J, Chandra A, Archibald P, Gold JD, Artzi N, Kim HW, Barker RW, Meissner A, Wu JC, Knowles JC, Williams D, García-Cardeña G, Sipp D, Oh S, Loring JF, Rao MS, Reeve B, Wall I, Carr AJ, Bure K, Stacey G, Karp JM, Snyder EY, Brindley DA. Enabling consistency in pluripotent stem cell-derived products for research and development and clinical applications through material standards. Stem Cells Transl Med. 2015 Mar;4(3):217-23. PubMed: 25650438.
  • Silva M, Daheron L, Hurley H, Bure K, Barker R, Carr AJ, Williams D, Kim HW, French A, Coffey PJ, Cooper-White JJ, Reeve B, Rao M, Snyder EY, Ng KS, Mead BE, Smith JA, Karp JM, Brindley DA, Wall I. Generating iPSCs: Translating Cell Reprogramming Science into Scalable and Robust Biomanufacturing Strategies. Cell Stem Cell. 2015 Jan 8;16(1):13-7. PubMed: 25575079
  • Smith JA, Naughton B, Kramm A, Smith G, Ohanjanyan A, De Simone M, Horne R, Brindley DA. European Union Falsified Medicines Directive: Requirements and Implications for Multi-Stakeholder Healthcare Delivery. Chapter 8 in Fundamentals of EU Regulatory Affairs, 7th Edition. Regulatory Affairs Professionals Society. Read on external site.
  • Smith JA, Bravery CA, Hollander G, Brindley DA. Regulating Regenerative Medicine: Cell Therapy, Gene Therapy and Tissue Engineering. Chapter 29 in Fundamentals of EU Regulatory Affairs, 7th Edition. Regulatory Affairs Professionals Society. Read on external site.
  • Smith JA, Reeve B, Carr A, Brindley DA. Regulating Regenerative Medicine: Cell Therapy, Gene Therapy and Tissue Engineering. Chapter 31 in Fundamentals of US Regulatory Affairs, 9th Edition. Regulatory Affairs Professionals Society. Read on external site.
  • Soland MA, Keyes LR, Bayne R, Moon J, Porada CD, St Jeor S, Almeida-Porada G. Perivascular stromal cells as a potential reservoir of human cytomegalovirus. Am J Transplant. 2014 Apr;14(4):820-30. doi: 10.1111/ajt.12642. Epub 2014 Mar 4 PubMed: 24592822
  • Meadows NA, Morrison A, Brindley DA, Schuh A, Barker RW. An evaluation of regulatory and commercial barriers to stratified medicine development and adoption. Pharmacogenomics J. 2015 Feb;15(1):6-12. doi: 10.1038/tpj.2014.51. Epub 2014 Oct 7. PubMed: 25287070.
  • Davies BM, Rikabi SR, French A, Pinedo-Villanueva R, Morrey ME, Wartolowska K, Brindley DA. Quantitative assessment of barriers to the clinical development and adoption of cellular therapies: A pilot study. J Tissue Eng. 2014 Sep 19;5:2041731414551764. doi: 10.1177/2041731414551764. eCollection 2014. PubMed: 25383173.
  • Smith G, Smith JA, Brindley DA. The Falsified Medicines Directive: How to secure your supply chain. J Generic Med. 2014 Sep;11(3-4):169-172. PubMed: 26435721.
  • French A, Suh JY, Suh CY, Rubin L, Barker R, Bure K, Reeve B, Brindley DA. Global strategic partnerships in regenerative medicine. Trends Biotechnol. 2014 Sep;32(9):436-40. doi: 10.1016/j.tibtech.2014.05.007. PubMed: 25150363.
  • Boura JS, Vance M, Yin W, Madeira C, Lobato da Silva C, Porada CD, Almeida-Porada G. Evaluation of gene delivery strategies to efficiently overexpress functional HLA-G on human bone marrow stromal cells. Mol Ther Methods Clin Dev. 2014 Sep;2014(1). pii: 14041. PubMed: 25279386.
  • Roberts M, Wall IB, Bingham I, Icely D, Reeve B, Bure K, French A, Brindley DA. The global intellectual property landscape of induced pluripotent stem cell technologies. Nat Biotechnol. 2014 Aug;32(8):742-8. doi: 10.1038/nbt.2975. PubMed: 25093884.
  • Elabd C, Cousin W, Upadhyayula P, Chen RY, Chooljian MS, Li J, Kung S, Jiang KP, Conboy IM. Oxytocin is an age-specific circulating hormone that is necessary for muscle maintenance and regeneration. Nat Commun. 2014 Jun 10;5:4082. doi: 10.1038/ncomms5082. PubMed: 24915299
  • Wartolowska K, Judge A, Hopewell S, Collins GS, Dean BJ, Rombach I, Brindley D, Savulescu J, Beard DJ, Carr AJ. Use of placebo controls in the evaluation of surgery: systematic review. BMJ. 2014 May 21;348:g3253. doi: 10.1136/bmj.g3253. PubMed: 24850821.
  • Planque SA, Nishiyama Y, Hara M, Sonoda S, Murphy SK, Watanabe K, Mitsuda Y, Brown EL, Massey RJ, Primmer SR, O’Nuallain B, Paul S. Physiological IgM class catalytic antibodies selective for transthyretin amyloid. J Biol Chem. 2014 May 9;289(19):13243-58. doi: 10.1074/jbc.M114.557231. PubMed: 24648510
  • Phay M, Blinder V, Macy S, Greene MJ, Wooliver DC, Liu W, Planas A, Walsh DM, Connors LH, Primmer SR, Planque SA, Paul S, O’Nuallain B. Transthyretin aggregate-specific antibodies recognize cryptic epitopes on patient-derived amyloid fibrils. Rejuvenation Res. 2014 Apr;17(2):97-104. doi: 10.1089/rej.2013.1524. PubMed: 24164623
  • Akman K, Haaf T, Gravina S, Vijg J, Tresch A. Genome-wide quantitative analysis of DNA methylation from bisulfite sequencing data. Bioinformatics. 2014 Jul 1;30(13):1933-4. doi: 10.1093/bioinformatics/btu142. Epub 2014 Mar 10. PubMed: 24618468.
  • Brindley DA, French AL, Baptista R, Timmins N, Adams T, Wall I, Bure K. Cell Therapy Bioprocessing Technologies and Indicators of Technological Convergence. BioProcess International 12(3)s (March 2014). Read on external site.
  • Chen Y, Ma X, Zhang M, Wang X, Wang C, Wang H, Guo P, Yuan W, Rudolph KL, Zhan Q, Ju Z. Gadd45a regulates hematopoietic stem cell stress responses in mice. Blood. 2014 Feb 6;123(6):851-62. doi: 10.1182/blood-2013-05-504084. PubMed: 24371210
  • French AL, Bure K, Brindley DA. CASMI TSCC Launch Event, Paris, France, July 2013: An Assessment of the Key Barriers to the Commercialization and Clinical Adoption of Pluripotent Stem Cell Therapies. Rejuvenation Res. February 2014, 17(1): 84-88. doi:10.1089/rej.2014.1545. PubMed: 24392658.
  • Rohani L, Johnson AA, Arnold A, Stolzing A. The aging signature: a hallmark of induced pluripotent stem cells? Aging Cell 2014;13(1):2-7. PubMed: 24256351.
  • Zhang J, Yang R, Zhou D, Rudolph KL, Meng A, Ju Z. Exonuclease 1 is essential for maintaining genomic stability and the proliferative capacity of neural but not hematopoietic stem cells. Stem Cell Res. 2014 Jan;12(1):250-9. doi: 10.1016/j.scr.2013.11.001. PubMed: 24280419
  • Rehki R, Wall I, French A, Bure K, Carr AJ, Brindley DA. Cell Therapy Biomanufacturing Risk Management. In: Cell Therapy Translation (D. Williams and D. Scadden, eds.), StemBook, 2014.
  • Chen Y, Yang R, Guo P, Ju Z. Gadd45a deletion aggravates hematopoietic stem cell dysfunction in ATM-deficient mice. Protein Cell. 2014 Jan;5(1):80-9. doi: 10.1007/s13238-013-0017-9. PubMed: 24474198
  • Bains, W. More than genes and cells: drug discovery in the ECM. Drug Discovery World. 2013/14 Winter:65-70. Read on external site. 
  • Brindley DA, French A, Suh J, Roberts M, Davies B, Pinedo-Villanueva R, Wartolowska K, Rooke K, Kramm A, Judge A, Morrey M, Chandra A, Hurley H, Grover L, Bingham I, Siegel B, Rattley MS, Buckler RL, McKeon D, Krumholz K, Hook L, May M, Rikabi S, Pigott R, Morys M, Sabokbar A, Titus E, Laabi Y, Lemaitre G, Zahkia R, Sipp D, Horne R, Bravery C, Williams D, Wall I, Snyder EY, Karp JM, Barker RW, Bure K, Carr AJ, Reeve B. The implementation of novel collaborative structures for the identification and resolution of barriers to pluripotent stem cell translation. Stem Cells Dev 2013;22 Suppl 1:63-72. PubMed: 24304079.
  • Brindley DA, Barker RW, Lachmann PJ. Health care: Better drug access for terminal patients. Nature. 2013 Oct 3;502(7469):38. doi: 10.1038/502038c. PubMed: 24091972
  • Wang T, Douglass EF Jr, Fitzgerald KJ, Spiegel DA. A “turn-on” fluorescent sensor for methylglyoxal. J Am Chem Soc. 2013 Aug 21;135(33):12429-33. doi: 10.1021/ja406077j. Epub 2013 Aug 9. PubMed: 23931147
  • Brindley DA, Wall IB. Commercial Manufacture of Cell Therapies. In: Standardization in Cell and Tissue Engineering: Methods and Protocols (V. Salih, ed.) Woodhead Publishing, 2012, pp. 212-240. Read on external site. 
  • Barker RW, Brindley DA, Schuh A. Establish good genomic practice to guide medicine forward. Nat Med. 2013 May;19(5):530. doi: 10.1038/nm0513-530. PubMed: 23652098.
  • Davalos AR, Kawahara M, Malhotra GK, Schaum N, Huang J, Ved U, Beausejour CM, Coppe JP, Rodier F, Campisi J. p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes. J Cell Biol 2013;201(4):613-29. PubMed: 23649808
  • French A, Buckler RL, Brindley DA. Commercialization of regenerative medicine: learning from spin-outs. Rejuvenation Res 2013;16(2):164-70. PubMed: 23470045
  • Brindley DA, Wall IB, Bure K. Automation of Cell Therapy Biomanufacturing: Minimizing Regulatory Risks and Maximising Return on Investment. Bioprocess International, Supplement; vol. 11, No. S3, March 2013, pp. 18–25.
 Read on external site. 
  • Kim T, Spiegel DA. The unique reactivity of N-phenacyl-derived thiazolium salts toward alpha-dicarbonyl compounds. Rejuvenation Res. 2013 Feb;16(1):43-50. doi: 10.1089/rej.2012.1370. PubMed: 23186164
  • Bates RC, Stith BJ, Stevens KE. Chronic central administration of valproic acid: Increased pro-survival phospho-proteins and growth cone associated proteins with no behavioral pathology. Pharmacol Biochem Behav 2012;103(2):237-44. PubMed: 22960225.
  • Johnson AA, Akman K, Calimport SR, Wuttke D, Stolzing A, de Magalhães JP. The role of DNA methylation in aging, rejuvenation, and age-related disease. Rejuvenation Res 2012;15(5):483-94. PubMed: 23098078
  • Mathieu JM, Wang F, Segatori L, Alvarez PJ. Increased resistance to oxysterol cytotoxicity in fibroblasts transfected with a lysosomally targeted Chromobacterium oxidase. Biotechnol Bioeng. 2012 Sep;109(9):2409-15. doi: 10.1002/bit.24506. PubMed: 22447444
  • Culme-Seymour EJ, Davie NL, Brindley DA, Edwards-Parton S, Mason C. A decade of cell therapy clinical trials (2000–2010). Regen Med. 2012 Jul;7(4):455-62. PubMed: 22817619
  • Wang T, Kartika R, Spiegel DA. Exploring post-translational arginine modification using chemically synthesized methylglyoxal hydroimidazolones. J Am Chem Soc. 2012 May 30;134(21):8958-67. PubMed: 22591136
  • Brindley DA, Davie NL, Sahlman WA, Bonfiglio GA, Culme-Seymour EJ, Reeve BC, Mason C. Promising growth and investment in the cell therapy industry during the first quarter of 2012. Cell Stem Cell. 2012 May 4;10(5):492-6. PubMed: 22560072
  • Brindley DA, Mason C. The Commercialisation of Cell Therapies. In: Progenitor and stem cell technologies and therapies: Principles and Issues (Vol 1). Woodhead Publishing (2012). Read on external site.
  • Davie ND, Brindley DA, Culme-Seymour EJ, Mason C. Streamlining Cell Therapy Manufacturing: From Clinical to Commercial Scale. BioProcess International. 10(3):24-29. Read on external site.
  • Brindley D, Reeve B, Mason C. Pharmaceutical industry: Investors unfazed by drug-patent expiry. Nature. 2012 Jan 18;481(7381):265. PubMed: 22258594.
  • Brindley DA, Davie NL, Culme-Seymour EJ, Mason C, Smith DW, Rowley JA. Peak serum: implications of serum supply for cell therapy manufacturing. Regen Med. 2012 Jan;7(1):7-13. doi: 10.2217/rme.11.112. PubMed: 22168489.
  • Brindley D, Mason C. Human embryonic stem cell therapy in the post-Geron era. Regen Med. 2012 Jan;7(1):17-8. doi: 10.2217/rme.11.115. PubMed: 22168491.
  • Brindley DA, Reeve BC, Sahlman WA, Bonfiglio GA, Davie NL, Culme-Seymour EJ, Mason C. The impact of market volatility on the cell therapy industry. Cell Stem Cell. 2011 Nov 4;9(5):397-401. PubMed: 22056137.
  • Brindley D, Moorthy K, Lee JH, Mason C, Kim HW, Wall I. Bioprocess forces and their impact on cell behavior: implications for bone regeneration therapy. J Tissue Eng. 2011;2011:620247. PubMed: 21904661
  • Mason C, Brindley DA, Culme-Seymour EJ, Davie NL. Cell therapy industry: billion dollar global business with unlimited potential. Regen Med. 2011 May;6(3):265-72. PubMed: 21548728.
  • Wu Y, Zhou J, Fishkin N, Rittmann BE, Sparrow JR. Enzymatic degradation of A2E, a retinal pigment epithelial lipofuscin bisretinoid. J Am Chem Soc. 2011 Feb 2;133(4):849-57. doi: 10.1021/ja107195u. PubMed: 21166406
  • Peto MV. Aluminium and iron in humans: bioaccumulation, pathology, and removal. Rejuvenation Res 2010 Oct;13(5):589-98. PubMed: 21142669
  • Rae MJ. SENS Foundation: Accelerating Progress Toward Biomedical Rejuvenation. In: Fahy GM, West M, Coles LS, Harris SB (eds). The Future of Aging: Pathways to Human Life Extension, Chapter: SENS Foundation: Accelerating Progress Toward Biomedical Rejuvenation. 2010; Springer Verlag, New York, pp. 806–826. Read on external site. 
  • Rae MJ, Butler RN, Campisi J, de Grey ADNJ, Finch CE, Gough M, Martin GM, Vijg J, Perrott KM, Logan BJ. The Demographic and Biomedical Case for Late-Life Interventions in Aging. Sci Transl Med. 2010 Jul 14;2(40):40cm21. PubMed: 20630854
  • Rebo J, Causey K, Zealley B, Webb T, Hamalainen M, Cook B, Schloendorn J. Whole-animal senescent cytotoxic T cell removal using antibodies linked to magnetic nanoparticles. Rejuvenation Res. 2010 Apr-Jun;13(2-3):298-300. doi: 10.1089/rej.2009.0964. PubMed: 20426617
  • Bussel II, Stupple A, Moody KJ, Lefkowitz DM. Call to action: medical students for regenerative medicine. Rejuvenation Res. 2010 Feb;13(1):1-2. PubMed: 20230272
  • Mathieu JM, Mohn WW, Eltis LD, LeBlanc JC, Stewart GR, Dresen C, Okamoto K, Alvarez PJ. 7-ketocholesterol catabolism by Rhodococcus jostii RHA1. Appl Environ Microbiol. 2010 Jan;76(1):352-5. doi: 10.1128/AEM.02538-09. PubMed: 19880645
  • Schloendorn J, Webb T, Kemmish K, Hamalainen M, Jackemeyer D, Jiang L, Mathieu J, Rebo J, Sankman J, Sherman L, Tontson L, Qureshi A, Alvarez P, Rittmann B. Medical bioremediation: a concept moving toward reality. Rejuvenation Res. 2009 Dec;12(6):411-9. doi: 10.1089/rej.2009.0917. PubMed: 20041735
  • Brindley DA, Davie N. Regenerative Medicine Through a Crisis: Social Perception and the Financial Reality. Rejuvenation Research 2009, 12(6): 455-461. PubMed: 20041739
  • Mathieu JM, Schloendorn J, Rittmann BE, Alvarez PJ. Medical bioremediation of age-related diseases. Microb Cell Fact. 2009 Apr 9;8:21. doi: 10.1186/1475-2859-8-21. PubMed: 19358742
  • Sjöberg JS, Bulterijs S. Characteristics, formation, and pathophysiology of glucosepane: a major protein cross-link. Rejuvenation Res 2009;12(2):137-48. PubMed: 19415980
  • Ellouze S, Augustin S, Bouaita A, Bonnet C, Simonutti M, Forster V, Picaud S, Sahel JA, Corral-Debrinski M. Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am J Hum Genet. 2008 Sep;83(3):373-87. doi: 10.1016/j.ajhg.2008.08.013. PubMed: 18771762
  • Mathieu J, Schloendorn J, Rittmann BE, Alvarez PJ. Microbial degradation of 7-ketocholesterol. Biodegradation. 2008;19(6):807-13. PubMed: 18344006
  • Rittmann BE, Schloendorn J. Engineering away lysosomal junk: medical bioremediation. Rejuvenation Res 2007;10(3):359-365. PubMed: 17708688
  • Bonnet C, Kaltimbacher V, Ellouze S, Augustin S, Bénit P, Forster V, Rustin P, Sahel JA, Corral-Debrinski M. Allotopic mRNA localization to the mitochondrial surface rescues respiratory chain defects in fibroblasts harboring mitochondrial DNA mutations affecting complex I or V subunits. Rejuvenation Res 2007;10(2):127-144. PubMed: 17518546

Research Blog

Coming Soon!

The CSO’s team expounds on the latest rejuvenation research and its implications for SENS.

Education Opportunities

SRF offers internships and fellowships to undergrads, postbacs, doctoral students, and post docs.

Receive our NewslEtter

Sign up to stay informed about the latest news and opportunities with SRF!

We respect your privacy. You can unsubscribe at any time.

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2019 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can